Prognostic role and mechanisms of abnormal coagulation system in lymphoma

Abstract

Chai Yue, Dong Mei. Prognostic role and mechanisms of abnormal coagulation system in lymphoma[J]. Journal of International Oncology, 2020, 47(10): 637-640.

References34

[1]	Sanfilippo KM, Wang TF, Gage BF, et al. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma[J]. Thromb Res, 2016,143:86-90. DOI: 10.1016/j.thromres.2016.05.008. doi:10.1016/j.thromres.2016.05.008pmid:27208462
[2]	Hohaus S, Tisi MC, Bartolomei F, et al. Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization[J]. Blood Cancer J, 2018,8(6):54. DOI: 10.1038/s41408-018-0096-1. doi:10.1038/s41408-018-0096-1pmid:29884791
[3]	Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis[J]. Cytometry A, 2016,89(2):111-122. DOI: 10.1002/cyto.a.22647. doi:10.1002/cyto.a.22647pmid:25704723
[4]	Ball S, Nugent K. Microparticles in hematological malignancies: role in coagulopathy and tumor pathogenesis[J]. Am J Med Sci, 2018,355(3):207-214. DOI: 10.1016/j.amjms.2017.11.014. doi:10.1016/j.amjms.2017.11.014pmid:29549921
[5]	Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis[J]. Semin Thromb Hemost, 2019,45(4):385-395. DOI: 10.1055/s-0039-1687894. doi:10.1055/s-0039-1687894pmid:31096306
[6]	Xia Q, Zhang X, Chen Q, et al. Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer[J]. J Cancer, 2020,11(5):1195-1202. DOI: 10.7150/jca.37321. doi:10.7150/jca.37321pmid:31956365
[7]	Han X, Guo B, Li Y, et al. Tissue factor in tumor microenvironment: a systematic review[J]. J Hematol Oncol, 2014,7:54. DOI: 10.1186/s13045-014-0054-8. doi:10.1186/s13045-014-0054-8pmid:25084809
[8]	Chi S, Ikezoe T. Disseminated intravascular coagulation in non-Hodgkin lymphoma[J]. Int J Hematol, 2015,102(4):413-419. DOI: 10.1007/s12185-015-1854-5. doi:10.1007/s12185-015-1854-5pmid:26272605
[9]	Falanga A, Russo L, Milesi V, et al. Mechanisms and risk factors of thrombosis in cancer[J]. Crit Rev Oncol Hematol, 2017,118:79-83. DOI: 10.1016/j.critrevonc.2017.08.003. doi:10.1016/j.critrevonc.2017.08.003pmid:28917273
[10]	Vlodavsky I, Singh P, Boyango I, et al. Heparanase: from basic research to therapeutic applications in cancer and inflammation[J]. Drug Resist Updat, 2016,29:54-75. DOI: 10.1016/j.drup.2016.10.001. doi:10.1016/j.drup.2016.10.001pmid:27912844
[11]	Lupu-Meiri M, Geras-Raaka E, Lupu R, et al. Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells[J]. J Cell Physiol, 2012,227(11):3621-3628. DOI: 10.1002/jcp.24068. doi:10.1002/jcp.24068
[12]	Chen N, Ren M, Li R, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma[J]. Mol Cancer, 2015,14:140. DOI: 10.1186/s12943-015-0418-x. doi:10.1186/s12943-015-0418-xpmid:26215730
[13]	Reitter EM, Ay C, Kaider A, et al. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients[J]. Clin Exp Immunol, 2014,177(1):253-260. DOI: 10.1111/cei.12308. doi:10.1111/cei.12308
[14]	Lee EC, Cameron SJ. Cancer and thrombotic risk: the platelet paradigm[J]. Front Cardiovasc Med, 2017,4:67. DOI: 10.3389/fcvm.2017.00067. doi:10.3389/fcvm.2017.00067pmid:29164134
[15]	Grilz E, Marosi C, Königsbrügge O, et al. Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer[J]. J Thromb Haemost, 2019,17(8):1335-1344. DOI: 10.1111/jth.14484. doi:10.1111/jth.14484pmid:31099477
[16]	Antonopoulos CN, Sfyroeras GS, Kakisis JD, et al. The role of soluble P selectin in the diagnosis of venous thromboembolism[J]. Thromb Res, 2014,133(1):17-24. DOI: 10.1016/j.thromres.2013.08.014. doi:10.1016/j.thromres.2013.08.014pmid:24012101
[17]	Mauracher LM, Posch F, Martinod K, et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients[J]. J Thromb Haemost, 2018,16(3):508-518. DOI: 10.1111/jth.13951. doi:10.1111/jth.13951pmid:29325226
[18]	Demers M, Wagner DD. Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression[J]. Oncoimmunology, 2013,2(2):e22946. DOI: 10.4161/onci.22946. doi:10.4161/onci.22946pmid:23526174
[19]	Zhou X, Teegala S, Huen A, et al. Incidence and risk factors of venous thromboembolic events in lymphoma[J]. Am J Med, 2010,123(10):935-941. DOI: 10.1016/j.amjmed.2010.05.021. doi:10.1016/j.amjmed.2010.05.021pmid:20920696
[20]	Abdel-Razeq H, Mansour A, Abdulelah H, et al. Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look![J]. Thromb J, 2018,16:2. DOI: 10.1186/s12959-018-0161-9. doi:10.1186/s12959-018-0161-9pmid:29507532
[21]	Riondino S, Ferroni P, Zanzotto FM, et al. Predicting VTE in cancer patients: candidate biomarkers and risk assessment models[J]. Cancers (Basel), 2019, 11(1). pii: E95. DOI: 10.3390/cancers11010095.
[22]	Mcalister RK, Ito S. Minimal prolongation of prothrombin time with extended exposure to argatroban[J]. Pharmacotherapy, 2015,35(7):e122-e126. DOI: 10.1002/phar.1613. doi:10.1002/phar.1613pmid:26147471
[23]	Fan S, Zhao G, An G. High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer[J]. J Int Med Res, 2019,47(1):215-224. DOI: 10.1177/0300060518799869. doi:10.1177/0300060518799869pmid:30270808
[24]	Malaguarnera M, Latteri S, Bertino G, et al. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis[J]. Clin Exp Gastroenterol, 2018,11:373-380. DOI: 10.2147/CEG.S172663. doi:10.2147/CEG.S172663pmid:30323642
[25]	Liang Y, He D, Wu L, et al. Elevated preoperative plasma D-dimer dose not adversely affect survival of gastric cancer after gastrectomy with curative intent: a propensity score analysis[J]. Chin J Cancer Res, 2018,30(2):254-262. DOI: 10.21147/j.issn.1000-9604.2018.02.08. doi:10.21147/j.issn.1000-9604.2018.02.08pmid:29861610
[26]	Lee S, Huh SJ, Oh SY, et al. Clinical significance of coagulation factors in operable colorectal cancer[J]. Oncol Lett, 2017,13(6):4669-4674. DOI: 10.3892/ol.2017.6058. doi:10.3892/ol.2017.6058pmid:28599468
[27]	Cao J, Fu Z, Gao L, et al. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma[J]. World J Surg Oncol, 2017,15(1):48. DOI: 10.1186/s12957-017-1104-9. doi:10.1186/s12957-017-1104-9pmid:28219450
[28]	Feng JF, Yang X, Chen S, et al. Prognostic value of plasma d-dimer in patients with resectable esophageal squamous cell carcinoma in China[J]. J Cancer, 2016,7(12):1663-1667. DOI: 10.7150/jca.15216. doi:10.7150/jca.15216pmid:27698903
[29]	Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer[J]. Br J Cancer, 2002,86(3):389-395. DOI: 10.1038/sj.bjc.6600069. doi:10.1038/sj.bjc.6600069pmid:11875705
[30]	Liu B, Li B, Zhou P, et al. Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL)[J]. Clin Chim Acta, 2018,482:191-198. DOI: 10.1016/j.cca.2018.04.013. doi:10.1016/j.cca.2018.04.013pmid:29649456
[31]	Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma[J]. Thromb Res, 2010,126(6):477-480. DOI: 10.1016/j.thromres.2010.08.017. doi:10.1016/j.thromres.2010.08.017pmid:21126629
[32]	Diao D, Cheng Y, Song Y, et al. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer[J]. BMC Cancer, 2017,17(1):56. DOI: 10.1186/s12885-016-3043-1. doi:10.1186/s12885-016-3043-1pmid:28086824
[33]	Berger MD, Heini AD, Seipel K, et al. Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia[J]. Hematol Oncol, 2017,35(4):789-796. DOI: 10.1002/hon.2307. doi:10.1002/hon.2307pmid:27301773
[34]	Elmoamly S, Afif A. Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?[J]. Hematology, 2018,23(2):89-95. DOI: 10.1080/10245332.2017.1365458. doi:10.1080/10245332.2017.1365458pmid:28823228

Prognostic role and mechanisms of abnormal coagulation system in lymphoma

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References34

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu.Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model[J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.